Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

NCT00146913 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT00146913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2004
Completion date
Not reported
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia